A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

NCT01340677 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Canagliflozin, 50 mg
DRUG: Canagliflozin, 300 mg
DRUG: Canagliflozin, 100 mg

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.